The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index; 4 of the 10 sources its claims cite were checked for support.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Open accessAbstract
BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. METHODS: CAR-positive (CAR+) T cells. The primary end point was an overall response (partial response or better); a key secondary end point was a complete response or better (comprising complete and stringent complete responses). RESULTS: nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better. The median progression-free survival was 8.8 months (95% confidence interval, 5.6 to 11.6). Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%). Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher. Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred. Cellular kinetic analysis confirmed CAR+ T cells in 29 of 49 patients (59%) at 6 months and 4 of 11 patients (36%) at 12 months after infusion. CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 10 cited sources checked · 2 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“The B-cell maturation antigen (BCMA)-directed CAR T cell idecabtagene vicleucel (ide-cel, also called bb2121) showed promising efficacy in a phase 1 study involving patients with relapsed or refractory myeloma.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > D
What the sources say
- Supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. source
The Methods identify bb2121 as an anti-BCMA CAR T-cell therapy studied in a phase 1 trial involving patients with relapsed or refractory multiple myeloma. The Discussion reports an 85% clinical response rate, supporting the characterization of its efficacy as promising. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Supportedcites [5] 5. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381: 727-38. source
The Methods and Discussion describe patients with triple-class refractory myeloma who were heavily pretreated, with a median of seven previous regimens. The Efficacy section reports median progression-free survival of 3.7 months with selinexor plus dexamethasone. This citation supports the selinexor result; the separate belantamab result is not attributed to this paper. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [17] 17. Lonial S, Lee HC, Badros A, et al. Belan- tamab mafodotin for relapsed or refracto- ry multiple myeloma (DREAMM-2): a two- arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207-21. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Observed toxic effects were consistent with those in previous reports.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. sourceExperimental — accuracy not yet measured
The Results (Safety; page unavailable) document the observed toxic effects. The Discussion compares them with previous studies, but reports a lower incidence of severe cytokine release syndrome with bb2121 and cautions that cross-study comparisons are complicated. It does not establish that the toxic effects were generally consistent with previous reports. (LLM, conf=0.82)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Duration of undetectable sBCMA correlated with response duration, and clearance of sBCMA at month 2 was associated with longer progression-free survival (Fig. S5E and S5F).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with peak levels higher in patients having cytokine release syndrome of grade 3 or higher (Fig. S6).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a somewhat higher frequency and somewhat greater depth of response were observed at the 450 × 10 6 dose (response in 81% of the pa-tients and complete response or better in 39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, 110 of 112 tumor samples (98%) expressed BCMA, with 109 having at least 50% BCMA-positive plasma cells, and all the patients had detectable levels of sBCMA.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedn = 112Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A response was observed in 73% of the treated patients, and a complete response or better was observed in 33%;”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline cytokine levels were not associated with higher-grade cytokine release syndrome or neurotoxic effects.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with an incidence of response to bridging therapy of 4%”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 12
- It may state two separate claims as one. 32
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, CD19 epitope loss is reported to be a relatively common escape mechanism after treatment with CD19-directed CAR T-cell therapy, especially in patients with acute leukemia.18,19”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [18] 18. Cheng J, Zhao L, Zhang Y, et al. Un- derstanding the mechanisms of resis- tance to CAR T-cell therapy in malignan- cies. Front Oncol 2019; 9: 1237. sourceExperimental — accuracy not yet measured
The Tumor Factors section reports that loss of the targeted CD19 epitope enabled escape after anti-CD19 CAR T-cell therapy in relapsed B-ALL. It also reports that target-antigen-negative relapse accounts for approximately 9–25% of B-ALL relapses, but does not establish that epitope loss specifically is relatively common or more common in acute leukemia than in other malignancies. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [19] 19. Badar T, Shah NN. Chimeric antigen receptor T cell therapy for acute lympho- blastic leukemia. Curr Treat Options On- col 2020; 21: 16. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with persistent grade 3 or 4 neutropenia (52 patients) or thrombocytopenia (62 patients) 1 month after infusion, the median time to recovery to grade 2 or lower was 1.9 months (range, 1.2 to 5.6) and 2.1 months (range, 1.2 to 13.8), respectively”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 52Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median progression-free survival was 8.8 months overall (95% CI, 5.6 to 11.6), 12.1 months (95% CI, 8.8 to 12.3) at the 450 × 10 6 dose, and 20.2 months (95% CI, 12.3 to could not be estimated) in patients having a complete or stringent complete response”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 128 treated patients had received a median of 6 previous antimyeloma regimens (range, 3 to 16), and 120 (94%) had received previous autologous hematopoietic stem-cell transplants (Table 1).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although high interpatient variability was observed at all doses, upper quartiles of exposure (area under the curve of the transgene level from time of dose to 28 days [AUC 0-28 days ]) were observed more frequently at the 450 × 10 6 dose (Fig. 3B).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among treated patients, 5 were positive for antidrug antibodies before infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline sBCMA levels were elevated in treated patients and de-creased rapidly after infusion in patients who had a response, with nadir values achieved within 3 months (Fig. 3A and Fig. S5B and S5C).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred.”
- Also stated in: § Table 1. (Continued.) · plain
“Investigator-identified neurotoxic effects were reported in 23 patients (18%), of whom 4 (3%) had grade 3 events; no grade 4 or 5 neu-rotoxic effects were observed”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time to first response was 1.0 month (range, 0.5 to 8.8); the median time to a complete response or better was 2.8 months (range, 1.0 to 11.8).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, neurotoxic effects of any grade were reported in 0 of 4 patients, 12 of 70 patients (17%), and 11 of 54 patients (20%), respectively, with grade 3 events in 0 patients, 1 patient (1%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 54Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median overall survival was 19.4 months (95% CI, 18.2 to could not be estimated), with an overall survival of 78% at 12 months (Fig. 2D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposures were higher in patients who had a response than in those who did not (Fig. S5A), and higher exposure was associated with deeper response and longer progression-free survival (Fig. 3C and 3D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Achievement of undetectable sBCMA levels increased with depth of response (17 of 27 pa-”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, cytokine release syndrome of any grade was observed in 2 of 4 patients (50%), 53 of 70 patients (76%), and 52 of 54 patients (96%), respectively, with cytokine release syndrome of grade 3 or higher observed in 0 patients, 4 patients (6%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimate for median duration of response was 10.7 months (95% CI, 9.0 to 11.3) overall and 11.3 months (95% CI, 10.3 to 11.4) at the 450 × 10 6 dose”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher.”
- Also stated in: § Table 1. (Continued.) · plain
“Cytokine release syndrome occurred in 107 patients (84%) and was mostly of grade 1 or 2 (Table 2 and Table S10).Five patients (4%) had grade 3 cytokine release syndrome, 1 (<1%) had grade 4, and 1 (<1%) had grade 5 (300 × 10 6 dose level).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 88 patients (69%) and were of grade 3 or 4 in 28 (22%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 88Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“including many with a high tumor burden, high-risk cytogenetic abnormalities, and extramedullary disease.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After disease progression, 28 patients were retreated with ide-cel (Table S4).Six patients (21%) had a second response, with durations of response ranging from 1.9 to 6.8 months; all the patients who had a response were retreated at a dose higher than their initial dose.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most grade 3 or 4 events were hematologic toxic effects, including neutropenia in 114 patients (89%), anemia in 77 (60%), and thrombocytopenia in 67 (52%), and were at least partially related to the lymphodepleting chemotherapy administered before ide-cel infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 114Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 44 treated patients (34%) died during the study, with most deaths (27) attributed by the investigator to complications of myeloma progression (Table S12).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 44Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Levels of proinflammatory markers, including cytokines, ferritin, and C-reactive protein, increased early after ide-cel infusion and decreased by month 1”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The response duration increased with the depth of response; the median response duration was 4.5 months (95% CI, 2.9 to 6.7), 10.4 months (95% CI, 5.1 to 11.3), and 19.0 months (95% CI, 11.3 to could not be estimated) in patients having a best response of partial response (27 patients), very good partial response (25 patients), and complete or stringent complete response (42 patients),”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the target doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, a response was observed in 2 of 4 patients (50%), in 48 of 70 patients (69%), and in 44 of 54 patients (81%), respectively, and a complete response or better was observed in 1 of 4 patients (25%), in 20 of 70 patients (29%), and in 21 of 54 patients (39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients (4%) died after 6 months from unrelated adverse events, and an additional 8 patients (6%) died after disease progression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 5Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Minimal residual disease (MRD)-negative status (<10 -5 nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better.”
- Also stated in: § Efficacy · plain
“Of the 42 patients with a complete or stringent complete response, 33 (79%) also had MRDnegative status at a sensitivity level of 10 -5 , corresponding to 26% (95% CI, 19 to 34) of the treated population; the remaining 9 patients (21%) could not be evaluated for MRD”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 33Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Efficacy · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“High-grade hematologic toxic effects were common but transient.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol was approved by local or independent institutional review boards or ethics committees at participating sites.All the patients provided written informed consent.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary efficacy analysis was performed in the population of patients treated with ide-cel (128 patients).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Between December 13, 2017, and November 13, 2018, a total of 140 patients were enrolled and underwent leukapheresis, of whom 128 received ide-cel infusions.Twelve patients discontinued the study before ide-cel infusion (including 1 patient who discontinued after unsuccessful manufacture of the CAR T-cell product)”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 140Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was designed by the authors in conjunction with the sponsors and conducted in accordance with the International Council for Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sample size for the primary end point (overall response) was based on a onesample binomial test with normal approximation, under the assumption of 15% dropout between the time of enrollment and ide-cel treatment.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Statistical tests were not performed on subgroup analyses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary end point was an overall response (partial response or better), defined according to IMWG Uniform Response Criteria for Multiple Myeloma 12 as assessed by an independent review committee.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“MRD negativity was evaluated in bone marrow aspirates by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) with a minimum cutoff of 10 -5 nucleated cells.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The actual doses delivered were within 20% of the target doses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Design and Patients
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.Cytokine release syndrome was graded according to published criteria (Table S2).14”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Soluble BCMA is a serum-based universal marker of myeloma burden.
“Soluble BCMA was assessed as a serum-based universal marker of myeloma burden.”
The paper relies on this without support.
Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
The paper relies on this without support.
MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
The paper relies on this without support.
BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
The paper relies on this without support.
The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are newly approved CAR-T products targeting BCMA that are active in relapsed refractory myeloma.89,90”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Safety of ide-cel remained consistent with the IA, with no parkinsonism, Guillain-Barré syndrome, or SPMs of T-cell origin reported. 13”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common side effects such as CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were mostly low grade, indicating manageable toxicity.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median duration of response (mDOR) was 11 months in patients achieving CR and 19 months in those achieving stringent complete response (sCR).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Median DOR and PFS were 10.7 months and 8.8 months, respectively, for ide-cel, and were both not reached for cilta-cel5,6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although follow-up is still ongoing, among patients with ≥CR, DOR and PFS at 15 months with elranatamab were comparable to those observed with other BCMA-targeted T-cell-redirecting therapies, suggesting similar outcomes once a deep response is achieved5,24,25.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High response rates have been reported with the BCMA chimeric antigen receptor (CAR) T-cell therapies, ide-cel and cilta-cel, with responses reported in 73% and 97% of treated patients, respectively.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among 128 patients with relapsed refractory myeloma treated on a phase II trial, ide-cel was associated with a response rate of 73%.89 Thirty three percent of patients had a complete response or better. The median PFS was 8.8 months.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome was seen in 84%, and 5% were grade 3 or higher. Neurotoxicity was seen in 18%, and was grade 3 in 3%.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Chimeric antigen receptor (CAR) T-cell therapy has shown promising ef fi cacy in patients with TCE R/RMM. 13-21”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In the KarMMa study involving 128 patients with RRMM, the overall response rate (ORR) to a single infusion of Abecma was 73%, with a complete response (CR) rate of 33%.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“Abecma has demonstrated the ability to induce rapid, deep, and long-lasting remissions with just one infusion, providing a new and effective personalized therapy option for MM patients [227, 243, 258, 259].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Recently approved therapies such as selinexor, 9 belantamab mafodotin, 10 idecabtagene vicleucel, 11 and ciltacabtagene autoleucel 12 have had clinical benefit in patients with relapsed or refractory multiple myeloma.”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [11]
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationOral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205
Treatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 181
CAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
Flagged first, then by citations
Cited by
Sorted by citations
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationLong-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,503
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Self-citationExploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Diagnosis and Management of Multiple Myeloma
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,082
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
“Among 128 patients with relapsed refractory myeloma treated on a phase II trial, ide-cel was associated with a response rate of 73%.(166) Thirty-three percent of patients had a CR or better.”
BackgroundIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationNatural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 810
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
“Indirect treatment comparisons between the CARTITUDE-1 results and real-world SOC, in data sets comprising European and/or US patients (MAMMOTH study and the prospective LocoMMotion study), found that cilta-cel significantly improved outcomes versus real-world therapies in triple-class exposed patients with RRMM.3,25…”
BackgroundResultInfluentialSelf-citationCAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C.-X., & Zhu, Z. G. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02327-z · Cited by 685
“Idecabtagene vicleucel (Abecma®) is the only FDAapproved CAR T therapy not targeting CD19 [5].”
BackgroundCAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 695
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02528-9 · Cited by 664
Self-citationMakni‐Maalej, K., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M. A., Maccalli, C., Cherif, H., Shahab Uddin, M. S., Steinhoff, M. S., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 662
“Currently, approved CAR-T cell therapy targets are mostly the B cell maturation antigen (BCMA) for multiple myeloma (MM) [8, 9] and the B cell antigen CD19 for various lymphoid malignancies including B-cell leukemias [10–12] and some types of lymphomas [13, 14].”
BackgroundClaudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Qi, C., Gong, J., Li, J., Liu, D., Qin, Y., Ge, S., Zhang, M., Peng, Z., Zhou, J., Cao, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01800-8 · Cited by 604
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
From bench to bedside: the history and progress of CAR T cell therapy
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q. F., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 526
“In April 2021 and February 2022, two BCMA-specific CAR T cell therapies were approved for the treatment of multiple myeloma, namely idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) (63, 64).”
BackgroundSelf-citationHayden, P. J., Roddie, C., Bader, P., Basak, G. W., Bonig, H. B., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.003 · Cited by 486
Self-citationThompson, J. A., Schneider, B. J., Brahmer, J. R., Achufusi, A., Armand, P. A., Berkenstock, M., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M. J., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0020 · Cited by 445
GPRC5D-Targeted CAR T Cells for Myeloma
Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., Russo, D., Auclair, R., Fitzgerald, L., Cadzin, B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209900 · Cited by 411
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 460
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Cappell, K. M., & Kochenderfer, J. N. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00530-z · Cited by 414
Snowden, J. A., Sánchez‐Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Cámara, R., Dolstra, H., Duarte, R. F., Glaß, B., Greco, R., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01691-w · Cited by 400
Self-citationNon-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
Zhang, J., Hu, Y., Yang, J., Li, W., Zhang, M., Wang, Q., Zhang, L., Wei, G., Tian, Y., Zhao, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05140-y · Cited by 397
CAR T Cells and T-Cell Therapies for Cancer
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 412
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
Lee, H., Ahn, S., Maity, R., Leblay, N., Ziccheddu, B., Truger, M. S., Chojnacka, M., Cirrincione, A. M., Durante, M. A., Tilmont, R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02491-5 · Cited by 370
Self-citationRejeski, K., Subklewe, M., Aljurf, M. D., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., et al. (2023) · Blood · doi:10.1182/blood.2023020578 · Cited by 395
Self-citationEngineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Dimitri, A. J., Herbst, F., & Fraietta, J. A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01559-z · Cited by 379
Usmani, S. Z., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., Miguel, J. F. S., Oriol, A., Rosiñol, L., Chari, A., Bhutani, M., Karlin, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01338-6 · Cited by 344
Self-citationCD8 T-cell subsets: heterogeneity, functions, and therapeutic potential
Koh, C., Lee, S., Kwak, M., Kim, B., & Chung, Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01105-x · Cited by 379
“More than seven ICI therapies 155 – 161 and six CAR-T-cell therapies 162 – 167 have been approved by the FDA for several types of malignancies.”
BackgroundExtramedullary disease in multiple myeloma: a systematic literature review
Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00643-3 · Cited by 319
“Published trials of other CAR-T therapies have reported responses in patients with soft-tissue plasmacytomas, but do not report data specifically for patients with EMD [44, 45].”
BackgroundSelf-citationXiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02148-6 · Cited by 347
“Timing Onset: 1–9 days after CAR T-cells infusion Duration: 5–11 days [81, 89, 118, 206–208, 210, 211, 213] Onset: 2–9 days after CAR T-cells infusion Duration: 3–17 days [89, 118, 207, 208, 213]”
Cohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N. W. C. J., Arnulf, B., Mateos, M.-V., Lendvai, N., Jackson, C. C., De Braganca, K. C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00629-1 · Cited by 308
Self-citationCurrent understanding and management of CAR T cell-associated toxicities
Brudno, J. N., & Kochenderfer, J. N. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00903-0 · Cited by 352
“In the initial pivotal trials of the currently approved CAR T cell therapies, use of anakinra for the management of active ICANS was limited to a few patients 10,11 , although this agent is now commonly used as the standard-of-care treatment for glucocorticoid-refractory ICANS 58,62 .”
InfluentialHansen, D. K., Sidana, S., Peres, L. C., Colin, C., Shune, L. O., Shrewsbury, A. M., Gonzalez, R. M., Sborov, D. W., Wagner, C. B., Dima, D., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01365 · Cited by 305
dos Santos, D. M. C., Tix, T., Shouval, R., Gafter-Gvili, A., Alberge, J.-B., Cliff, E. R. S., Theurich, S., von Bergwelt-Baildon, M., Ghobrial, I., Subklewe, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03084-6 · Cited by 266
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
Fonkoua, L. A. K., Sirpilla, O. L., Sakemura, R. L., Siegler, E. L., & Kenderian, S. S. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.03.009 · Cited by 316
Oekelen, O. V., Aleman, A., Upadhyaya, B., Schnakenberg, S., Madduri, D., Gavane, S. C., Teruya‐Feldstein, J., Crary, J. F., Fowkes, M. E., Stacy, C. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01564-7 · Cited by 294
Self-citationCAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens‐Arias, V., Díaz‐Beyá, M., Juan, M., Urbano-Ispizúa, Á., Esteve, J., Velasco-Hernández, T., & Menéndez, P. R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 350
T-cell-engaging bispecific antibodies in cancer
van de Donk, N. W. C. J., & Zweegman, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00521-4 · Cited by 275
Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02182-7 · Cited by 257
Advancements and challenges in CAR T cell therapy in autoimmune diseases
Schett, G. A., Müller, F., Taubmann, J., Mackensen, A., Wang, W., Furie, R., Gold, R., Haghikia, A., Merkel, P. A., Caricchio, R., et al. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01139-z · Cited by 281
“Indeed, CAR T cells against BCMA are currently employed in the treatment of multiple myeloma 63 .”
Cancer therapy with antibodies
Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., & Zhou, S. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00690-x · Cited by 292
“The first nanobody-based CAR T cell targeting BCMA has received FDA approval 253 and demonstrated improved efficacy when compared with antibody-based CAR T cells 254 .”
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
Greenberger, L. M., Saltzman, L. A., Senefeld, J. W., Johnson, P. W., DeGennaro, L. J., & NICHOLS, G. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.012 · Cited by 247
Synthetic cytokine circuits that drive T cells into immune-excluded tumors
Allen, G. M., Frankel, N. W., Reddy, N. R., Bhargava, H. K., Yoshida, M. A., Stark, S. R., Purl, M. C., Lee, J., Yee, J. L., Yu, W., et al. (2022) · Science · doi:10.1126/science.aba1624 · Cited by 251
“C himeric antigen receptor (CAR) T cells have demonstrated remarkable success in the treatment of B cell malignancies (1, 2).”
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Mei, H., Li, C., Jiang, H., Zhao, X., Huang, Z., Jin, D., Guo, T., Kou, H., Liu, L., Tang, L., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01170-7 · Cited by 222
The journey of CAR-T therapy in hematological malignancies
Lu, J., & Jiang, G. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01663-0 · Cited by 240
“This product can be used to treat adult patients with R/R MM after fourth-line or more therapy, including immunomodulatory, proteasome inhibitors and anti-CD38 monoclonal antibodies [85].”
BackgroundMethodInfluentialShy, B. R., Vykunta, V. S., Ha, A. S., Talbot, A., Roth, T. L., Nguyen, D. N., Pfeifer, W. G., Chen, Y. Y., Blaeschke, F., Shifrut, E., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01418-8 · Cited by 223
Cohen, A. D., Mateos, M., Cohen, Y. C., Rodríguez‐Otero, P., Paiva, B., van de Donk, N. W. C. J., Martin, T., Suvannasankha, A., Braganca, K. C. D., Corsale, C., et al. (2022) · Blood · doi:10.1182/blood.2022015526 · Cited by 224
Recent advances in overcoming barriers to cell‐based delivery systems for cancer immunotherapy
Ding, Y., Wang, Y., & Hu, Q. (2022) · Exploration · doi:10.1002/exp.20210106 · Cited by 213
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Callander, N. S., Baljević, M., Adekola, K., Anderson, L. D., Campagnaro, E. L., Castillo, J. J., Costello, C. L., Devarakonda, S. S., Elsedawy, N., Faiman, M., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0002 · Cited by 210
Self-citationThe future of engineered immune cell therapies
Irvine, D. J., Maus, M. V., Mooney, D. J., & Wong, W. W. (2022) · Science · doi:10.1126/science.abq6990 · Cited by 215
CAR-T cell performance: How to improve their persistence?
López-Cantillo, G., Urueña, C., Camacho, B. A., & Ramírez-Segura, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878209 · Cited by 207
“Recently, the FDA has approved a CAR-T cell immunotherapy for multiple myeloma; the first-in-class B-cell maturation antigen (BCMA)-targeted CAR-T cell therapy received the agency’s approval on March 26, 2021, to treat adults with relapsed/refractory multiple myeloma (9, 10).”
BackgroundDagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 229
“This study showed an overall response in 73% of the heavily pre-treated patients with r/r MM, with a CR in 33% of the cases [155].”
BackgroundRisk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., Kang, X., Olsen, M. N., Good, Z., Dahiya, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401361 · Cited by 223
“Despite the remarkable therapeutic efficacy of commercial chimeric antigen receptor (CAR) T-cell therapies, 1-9 concerns over toxicities remain.”
Ludwig, H., Terpos, E., van de Donk, N. W. C. J., Mateos, M., Moreau, P., Dimopoulos, M. A., Delforge, M., Rodríguez‐Otero, P., Miguel, J. F. S., Yong, K., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00159-6 · Cited by 226
Self-citationCAR-T Cell Therapy: the Efficacy and Toxicity Balance
Chohan, K. L., Siegler, E. L., & Kenderian, S. S. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00687-7 · Cited by 227
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Saura‐Esteller, J., de Jong, M., King, L. A., Ensing, E., Winograd, B., de Gruijl, T. D., Parren, P. W. H. I., & van der Vliet, H. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915837 · Cited by 210
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M. L., Arnason, J. E., Purev, E., Maloney, D. G., Andreadis, C. B., Sehgal, A. R., et al. (2023) · Blood · doi:10.1182/blood.2023020854 · Cited by 199
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Dejenie, T. A., Medhin, M. T. G., Terefe, G. D., Admasu, F. T., Tesega, W. W., & Abebe, E. C. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2114254 · Cited by 210
“Side effects such as CRS and neurotoxicity were low, accounting for 5% and 3%, respectively.(160,161)”
BackgroundLinvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
Bumma, N., Richter, J. R., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01008 · Cited by 191
Successes and challenges in clinical gene therapy
Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00390-5 · Cited by 209
A genome-scale screen for synthetic drivers of T cell proliferation
Legut, M., Gajic, Z. Z., Guarino, M., Daniloski, Z., Rahman, J. A., Xue, X., Lu, C., Lu, L., Mimitou, E. P., Hao, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04494-7 · Cited by 180
Applications of synthetic biology in medical and pharmaceutical fields
Yan, X., Liu, X., Zhao, C., & Chen, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01440-5 · Cited by 191
From concept to cure: The evolution of CAR-T cell therapy
Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N., & June, C. H. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.005 · Cited by 211
Lickefett, B., Chu, L., Ortiz‐Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D. A., Hudecek, M., Kremer, A., Markman, J. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303935 · Cited by 200
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 197
“Finally, in multiple myeloma, a complete remission to therapy was achieved in 67–79% across the two approved BCMA-targeted products: idecabtagene vicleucel and ciltacabtagene autoleucel 7,8 .”
BackgroundCAR T-cell therapy in multiple myeloma: more room for improvement
Teoh, P. J., & Chng, W. J. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00469-5 · Cited by 179
Drug delivery systems for CRISPR-based genome editors
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 193
Zhang, M., Wei, G., Zhou, L., Zhou, J., Chen, S., Zhang, W., Wang, D., Luo, X., Cui, J., Huang, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00372-6 · Cited by 166
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Zhang, X., Zhang, H., Lan, H., Wu, J., & Xiao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1101495 · Cited by 181
“In general, bridging therapies with previously effective therapeutic agents can be considered, such as dexamethasone, daratumumab, carfilzomib, bortezomib, and pomalidomide (113).”
BackgroundCAR T therapies in multiple myeloma: unleashing the future
Sheykhhasan, M., Ahmadieh-Yazdi, A., Vicidomini, R., Poondla, N., Tanzadehpanah, H., Dirbaziyan, A., Mahaki, H., Manoochehri, H., Kalhor, N., & Dama, P. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00750-2 · Cited by 183
Dimopoulos, M., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hájek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 188
“This approval was based on the results of the phase II KarMMa trial 116 , in which 128 patients who had received three or more lines of therapy, including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody, were treated with ide-cel.”
Self-citationImmunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 181
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
Bahlis, N. J., Costello, C. L., Raje, N. S., Levy, M. Y., Dholaria, B., Solh, M., Tomasson, M. H., Damore, M. A., Jiang, S., Basu, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02589-w · Cited by 162
Self-citationMultiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Baz, R., Campagnaro, E. L., Castillo, J. J., Costello, C. L., D'Angelo, C. R., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0061 · Cited by 174
Self-citationT cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A., & Ribas, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00809-z · Cited by 164
“Unlike T cell-based therapies that have received FDA approval in the relapsed/refractory setting on the basis of high overall response rates in single-arm phase II trials 281–287 , a soluble bispecific TCR registration trial would require a randomized design.”
BackgroundAdverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy
Goldman, A., Maor, E., Bomze, D., Liu, J. E., Herrmann, J., Fein, J. A., Steingart, R. M., Mahmood, S., Schaffer, W. L., Perales, M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.044 · Cited by 159
Elsallab, M., Ellithi, M., Lunning, M. A., D'Angelo, C. R., Ma, J., Perales, M., Frigault, M. J., & Maus, M. V. (2024) · Blood · doi:10.1182/blood.2024024166 · Cited by 157
The Past, Present, and Future of Non-Viral CAR T Cells
Moretti, A., Ponzo, M., Nicolette, C. A., Tcherepanova, I. Y., Biondi, A., & Magnani, C. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867013 · Cited by 167
Grant, S. J., Grimshaw, A. A., Silberstein, J., Murdaugh, D. L., Wildes, T. M., Rosko, A. E., & Giri, S. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.03.006 · Cited by 158
Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J. R., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00223-1 · Cited by 170
Self-citationChimeric antigen receptor T cell therapy for autoimmune disease
Chung, J. B., Brudno, J. N., Borie, D. C., & Kochenderfer, J. N. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01035-3 · Cited by 159
Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access
Ahmed, N., Shahzad, M., Shippey, E., Bansal, R., Mushtaq, M. U., Mahmoudjafari, Z., Faisal, M. S., Hoffmann, M. S., Abdallah, A.-O. A., Divine, C. L., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.04.008 · Cited by 146
Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 163
“5 Idecabtagene Vicleucel (ABECMATM) On March 2021, idecabtagene vicleucel (ABECMATM) from Bristol Myers Squibb was approved as the first cell-based immunotherapy for adult patients with r/r multiple myeloma after four or more preceded lines of therapy, including an anti-CD38 monoclonal antibody, an immunomodulator, an…”
BackgroundMetabolic challenges and interventions in CAR T cell therapy
Peng, J.-J., Wang, L., Li, Z., Ku, C., & Ho, P. (2023) · Science Immunology · doi:10.1126/sciimmunol.abq3016 · Cited by 156
Zhao, W., Wang, B., Chen, L., Fu, W., Xu, J., Liu, J., Jin, S., Chen, Y., Cao, X.-M., Yang, Y., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01301-8 · Cited by 143
“Seventy‑four participants with RRMM received LCAR‑B38M treatment.”
BackgroundInfluentialDeterminants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Sworder, B. J., Kurtz, D. M., Alig, S., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Esfahani, M. S., Olsen, M. N., Hamilton, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.005 · Cited by 147
Lancman, G., Parsa, K., Kotlarz, K., Avery, L., Lurie, A., Lieberman-Cribbin, A., Cho, H. J., Parekh, S. S., Richard, S., Richter, J., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0049 · Cited by 140
Co-Stimulatory Receptor Signaling in CAR-T Cells
Honikel, M. M., & Olejniczak, S. H. (2022) · Biomolecules · doi:10.3390/biom12091303 · Cited by 149
Rejeski, K., Hansen, D. K., Bansal, R., Sesques, P., Ailawadhi, S., Logue, J., Bräunlein, E., dos Santos, D. M. C., Freeman, C., Alsina, M., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01465-x · Cited by 140
“Lymphodepleting chemotherapy with fludarabine and cyclophosphamide was administered according to the manufacturers’ instructions [1, 2].”
MethodSelf-citationWudhikarn, K., & Perales, M. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01756-w · Cited by 151
“In addition, two CAR T-cells products against B cell maturation antigen (BCMA) were also recently approved for patients with refractory multiple myeloma (MM) [8, 9].”
BackgroundHow I Treat Cytopenias after CAR T-cell Therapy
Jain, T., Olson, T. S., & Locke, F. L. (2023) · Blood · doi:10.1182/blood.2022017415 · Cited by 148
Roadmap to cure multiple myeloma
Rodríguez‐Otero, P., Paiva, B., & Miguel, J. F. S. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102284 · Cited by 146
“Regarding antibody-drug conjugates targeting BCMA, belantamab mafodotin was recently approved by the Food and Drug Administration (FDA) and by the European Medicine Agencies (EMA) for the treatment of adult patients with relapse and refractory MM (RRMM) who have received at least 4 prior lines of therapy including a p…”
BackgroundD’Souza, A., Shah, N. D., Rodriguez, C., Voorhees, P. M., Weisel, K. C., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01504 · Cited by 134
“30 days from last dose 7 (14) 12 (15) 30 (24)”
Self-citationImmunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
Huang, H., Yao, Y., Deng, X., Huang, Z., Chen, Y., Wang, Z., Hong, H., Huang, H., & Lin, T. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5545 · Cited by 141
Recent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 140
“Idecabtegene vicleucel was approved in 2021, based on a phase 2 study showing that heavily pre-treated, relapsed refractory patients achieved 73% ORR and 33% CR rate [71].”
MethodThiruvengadam, S. K., Sheng, Y., Huang, C.-Y., Bylsma, S., Lo, M., Kennedy, V., Natsuhara, K., Martin, T., Wolf, J., Shah, N., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2020004079 · Cited by 131
“Using chimeric antigen receptor T cell therapy (CAR-T) against 65 CD19 in lymphoma has been quite successful and recently idecabtagene vicleucel B-cell 66 maturation antigen-directed CAR-T therapy (BCMA CAR-T) gained FDA approval for RRMM.1 67 Toxicities associated with CAR-T therapy include cytokine release syndrome…”
BackgroundSelf-citationWang, Y., Cao, J., Gu, W., Shi, M., Lan, J., Yan, Z., Jin, L., Xia, J., Ma, S., Liu, Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01676 · Cited by 132
“Previous therapy lines, median (range) 4 (2-17)”
Direct in vivo CAR T cell engineering
Short, L., Holt, R. A., Cullis, P. R., & Evgin, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.03.004 · Cited by 141
Metadata
- Authors
- Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F., Massaro, M., Connarn, J. N., Kaiser, S., Patel, P., Huang, L., Campbell, T. B., Hege, K., & San-Miguel, J.
- Affiliations
- Harvard University (US)
- Mayo Clinic (US)
- Hackensack University Medical Center (US)
- From the Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute (N.C.M.), the Veterans Affairs Boston Healthcare System, Harvard Medical School (N.C.M.), and Massachusetts General Hospital (N.R.), Boston, and bluebird bio, Cambridge (F.P., M.M.) — all in Massachusetts; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.); the University of California, San Francisco, San Francisco (N.S.); Icahn School of Medicine at Mount Sinai, New York ...
- ORCID
- Munshi, Nikhil C.
- Anderson, Larry D.
- Shah, Nina
- Madduri, Deepu
- Berdeja, Jesús
- Lonial, Sagar
- Raje, Noopur
- Lin, Yi
- Siegel, David
- Oriol, Albert
- Moreau, Philippe
- Yakoub-Agha, Ibrahim
- Delforge, Michel
- Einsele, Hermann
- Goldschmidt, Hartmut
- Weisel, Katja
- Rambaldi, Alessandro
- Reece, Donna
- Petrocca, Fabio
- Connarn, Jamie N.
- Kaiser, Shari
- Patel, Payal
- Huang, Liping
- Campbell, Timothy B.
- Hege, Kristen
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-25
- Volume
- 384
- Issue
- 8
- Pages
- 705-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3133229959
- Semantic Scholar
- fd96e2f87dff7d1153a17b78b56fbbab69cb714e
- Cited by
- 2,560
- References
- 17
- Citations by year
- 2026: 411 · 2025: 486 · 2024: 540 · 2023: 493 · 2022: 436 · 2021: 186
- FWCI
- 150.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- idecabtagene vicleucel, CAR T-cell therapy, relapsed/refractory multiple myeloma, BCMA, minimal residual disease, cytokine release syndrome, neurotoxicity, CAR T cell persistence, progression-free survival, complete response, neutropenia, anemia, thrombocytopenia, chimeric antigen receptor T cells
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Cytokine Release Syndrome, Adult, Aged, Female, Hematologic Diseases, Humans, Male, Middle Aged, Multiple Myeloma, Recurrence, Biomarkers, Immunotherapy, Adoptive, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
